Key Takeaways The Johnson & Johnson (JNJ) stock has risen 4.4% in six months, adding more than $15 billion to its market value. J&J separated its Consumer Health business into a newly listed company called Kenvue (KVUE) in 2023. The separation of Kenvue has allowed J&J to focus on its core pharmaceutical and medical device business. JNJ's Innovative Medicine Unit: A Bright Spot J&J faces several challenges, including slowing sales in the MedTech segment, loss of exclusivity of its blockbuster drug, Stelara, ...